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Iris Metastasis in Small-Cell Lung Carcinoma
Anke W. J. Roenhorst, MD,* Alphons C. M. van den Bergh, MD,† John W. G. van Putten, MD, PhD,‡
and Egbert F. Smit, MD, PhD§
Small-cell lung cancer (SCLC) is characterized by rapid growth and
early metastasis. Despite its sensitivity to cytotoxic treatment, until
now treatments have failed to control or cure this disease in most
patients.
Here, we describe a patient with SCLC in which symptoms
caused by iris metastasis were the only sign of relapse after multi-
modality treatment.
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A 58-year-old woman was referred to the department ofpulmonary medicine with a history of cough, dyspnea,
and weight loss. Ultimately, small-cell lung cancer (SCLC) of
the right lower lobe, limited disease (involvement of medi-
astinal lymph nodes Naruke 2, 4, and 7; there were no distant
metastases), was diagnosed. She was treated with five cycles
of cyclophosphamide, doxorubicin, and etoposide, and then
thoracic radiotherapy (25 fractions of 2 Gy, total dose of 50
Gy) and prophylactic cranial irradiation (15 fractions of 2 Gy,
total dose of 30 Gy). Appropriate field arrangements and
blocking were used to shield the patient’s eyes. A near-
complete remission was achieved. The treatment course was
complicated by an episode of radiation pneumonitis, which
was treated successfully with prednisolone. Eighteen months
after completion of treatment, the patient presented with a 2
weeks’ history of a white spot in her right eye, without
disturbance of her vision. Two amelanotic tumors in the iris
were observed at the 4-o’clock and 6-o’clock meridians in the
right iris, characteristic for iris metastases. One of the two
lesions showed prominent blood vessels (Figure 1). Intraoc-
ular pressure was not elevated, and fundoscopy was normal.
No abnormalities were found on examination of the left eye.
Restaging, including laboratory examinations, chest x-ray,
and magnetic resonance imaging of the cerebrum, did not
show a local recurrence or other distant metastases. Given the
characteristic appearance, in combination with the history of
SCLC, a biopsy was not taken.
The iris metastases were treated with external beam
radiotherapy, using a 6-MV photon linear accelerator. Using
two wedged fields coming from the caudal and cranial direc-
tions, the right eye was irradiated with 25 fractions of 1.8 Gy,
with a total dose of 45 Gy. After 25.2 Gy, the iris metastases
decreased in size, and the pain vanished. At a dose of 41.4
Gy, a further regression of the metastases was observed. As a
result of radiotherapy, secondary glaucoma developed and
was resistant to local therapy. Ultimately, enucleation of the
right eye was performed 18 months after radiotherapy. Patho-
logic examination of the removed eye still showed active,
metastatic SCLC (Figure 2).
Five years after the initial presentation, the patient is
alive without other recurrences of her disease.
DISCUSSION
Metastases to the central nervous system are a frequent
complication in the clinical course of SCLC. At autopsy, up
to 50% of the patients with SCLC have intracranial metasta-
ses.1 Of all ocular metastases, uveal metastasis is the most
common form of ocular malignancy. The choroid is the most
common site for uveal metastasis; metastasis to the ciliary
body, retina, optic disc, vitreous, and iris are rare.2 Metastasis
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FIGURE 1. Two amelanotic tumors in the iris at the
4-o’clock and 6-o’clock meridians, characteristic for an iris
metastasis. One of the two lesions shows prominent blood
vessels
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to the iris can be easily confused with uveitis of nonmalignant
origin. Lung and breast cancer represent more than two thirds
of the primary tumor sites. Approximately one third of the
patients have no history of primary cancer at the time of
ocular diagnosis.3,4 The iris mass was the first sign of meta-
static disease in more than three quarters of the patients in a
study from Shields and coworkers.3 In this study, coexisting
brain metastases were detected on computed tomography or
magnetic resonance imaging in 44% of the patients with iris
metastasis. After diagnosing solitary iris metastasis, the ma-
jority of patients subsequently develop clinical evidence of
systemic metastasis in a few months.3 Iris metastasis most
often are unilateral, but bilateral metastases do occur.4
The chief complaints with iris metastases are blurred
vision, ocular pain, redness, visible iris mass, or photophobia.
Iris metastasis present most often as a yellow-white solitary
nodule in the inferior quadrant.3 The differential diagnosis
includes nonpigmented lesions such as amelanotic mela-
noma, amelanotic nevus, granulomatous iritis, lymphoma,
leukemia, and leiomyoma.3 The diagnosis of iris metastasis
generally is based on historical and clinical findings. A
rapidly enlarging mass in the presence of a history of a
previously treated malignancy should raise the suspicion of
an iris metastasis. If the diagnosis is uncertain, fine-needle
aspiration biopsy of the iris mass can be used for cytologic
verification.5
The management of uveal metastasis is focused on
palliation and preservation of eye function. When there is
systemic involvement, treatment consists of systemic therapy.
If local control is not achieved, or when there is a solitary
uveal metastasis, external beam radiation or plaque radiother-
apy is the treatment of choice. Enucleation is only recom-
mended when the eye becomes blind and painful.3
Survival times for patients with iris metastasis from
lung carcinoma range from 1 to 18 months, with a mean of 7
months and a median of 4 months.3 Our patient is still alive
3 years after the diagnosis of iris metastasis.
In conclusion, iris metastases of SCLC are very rare
and can be considered as central nervous system metastases.
Treatment with radiotherapy usually provides good pallia-
tion, but sometimes enucleation is necessary.
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FIGURE 2. Low-power view of one of the metastatic le-
sions. The tumor is located in the ciliary body. Vital areas of
the tumor (blue) alternate with necrotic fields (pink). Hema-
toxylin/eosin stain, 20.
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